title: Effects of CYP2D6 polymorphisms on neuroleptic malignant syndrome.
abstract: OBJECTIVE
  Neuroleptic malignant syndrome (NMS) is one of the most serious adverse reactions to antipsychotic medications. We accumulated data on Japanese NMS patients and, in a study designed to examine the effects of drug metabolism on the occurrence of NMS, tested the possibility of association between NMS and CYP2D6 polymorphisms.
  
  
  METHODS
  We studied 53 patients who had experienced NMS and 112 healthy individuals. We determined what drugs the patients with NMS had been given and retrospectively identified candidates for drugs causing NMS. We screened the prevalence of CYP2D6 genotypes using polymerase chain reaction and restriction fragment length polymorphism analyses.
  
  
  RESULTS
  The prevalence of *5 alleles in the group of all patients with NMS was higher than that in the controls, though this difference was not statistically significant (10.4% vs. 5.4%; P = 0.107; odds ratio (OR) 2.05; 95% confidence interval (CI) 0.87-4.80). No association was found between the frequency of *10 alleles and the occurrence of NMS. We found *4 and duplicated alleles in only one patient each among the patients with NMS. A total of 29 patients appeared to have developed NMS as a result of having taking CYP2D6 substrates. The prevalence of *5 alleles in these 29 patient was significantly higher than that in the controls (15.5% vs. 5.4%; P = 0.020; OR 3.25; 95% CI 1.30-8.13).
  
  
  CONCLUSIONS
  Our findings suggest that the CYP2D6*5 allele is likely to affect vulnerability to development of NMS.
authors: Department of Psychiatry, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa, 236-0004, Japan.
authors: Daiji
authors: D
authors: Kato
authors: Chiaki
authors: C
authors: Kawanishi
authors: Ikuko
authors: I
authors: Kishida
authors: Taku
authors: T
authors: Furuno
authors: Kyoko
authors: K
authors: Suzuki
authors: Hideki
authors: H
authors: Onishi
authors: Yoshio
authors: Y
authors: Hirayasu
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000483:Alleles; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000493:pharmacokinetics; D044466:Asian People / Q000235:genetics; D016022:Case-Control Studies; D002648:Child; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics* / Q000378:metabolism; D005260:Female; D017353:Gene Deletion; D005838:Genotype; D006801:Humans; D007564:Japan; D008297:Male; D008875:Middle Aged; D009459:Neuroleptic Malignant Syndrome / Q000235:genetics*; D016017:Odds Ratio; D011110:Polymorphism, Genetic; D012150:Polymorphism, Restriction Fragment Length; D015995:Prevalence; D012189:Retrospective Studies; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D014150:Antipsychotic Agents; D019389:Cytochrome P-450 CYP2D6
references: J Neurol Sci. 1998 Sep 18;160(1):102-4
references: 9804127
references: Neuropsychopharmacology. 2003 Aug;28(8):1501-5
references: 12784098
references: Psychiatr Genet. 2000 Mar;10(1):9-11
references: 10909122
references: Gene. 1999 Jan 21;226(2):327-38
references: 9931507
references: Biol Psychiatry. 1994 Dec 1;36(11):781-2
references: 7858079
references: Psychiatry Clin Neurosci. 2005 Aug;59(4):504-7
references: 16048458
references: Pharmacogenetics. 1996 Aug;6(4):351-5
references: 8873221
references: J Clin Psychiatry. 2004 Apr;65(4):464-70
references: 15119907
references: Arch Gen Psychiatry. 1989 Oct;46(10):914-8
references: 2572206
references: Clin Pharmacol Ther. 1993 Apr;53(4):410-8
references: 8097442
references: Br J Clin Pharmacol. 2002 Feb;53(2):111-22
references: 11851634
references: Am J Psychiatry. 1997 Aug;154(8):1156-8
references: 9247408
references: Psychiatr Genet. 2000 Sep;10(3):145-7
references: 11204351
references: Schizophr Res. 1998 Jul 27;32(2):101-6
references: 9713905
references: Psychopharmacology (Berl). 1997 May;131(2):174-9
references: 9201806
references: Psychiatr Genet. 1997 Autumn;7(3):127-9
references: 9323326
references: Br J Clin Pharmacol. 2000 Jul;50(1):31-4
references: 10886115
references: Clin Genet. 1991 Jan;39(1):65-7
references: 1997219
references: Ther Drug Monit. 2003 Jun;25(3):287-93
references: 12766554
references: Pharmacogenomics. 2002 Mar;3(2):201-18
references: 11972442
references: Pharmacogenetics. 1999 Dec;9(6):707-14
references: 10634133
references: Mol Psychiatry. 2004 Mar;9(3):293-8
references: 15094790
references: Pharmacogenetics. 2000 Aug;10(6):567-70
references: 10975611
references: Aust N Z J Psychiatry. 2000 Aug;34(4):699-700
references: 10954409
references: Biol Psychiatry. 1998 Oct 15;44(8):748-54
references: 9798079
references: Drug Intell Clin Pharm. 1988 Jun;22(6):475-80
references: 2899492
references: J Clin Psychopharmacol. 1998 Aug;18(4):349-51
references: 9690707
references: Am J Psychiatry. 1986 Oct;143(10):1227-33
references: 2876647
references: Pharmacopsychiatry. 1987 Jul;20(4):168-70
references: 3615574
references: Psychopharmacol Bull. 1988;24(1):25-9
references: 3290944
references: Folia Psychiatr Neurol Jpn. 1977;31(4):559-76
references: 608659
references: Schizophr Res. 1998 Jul 27;32(2):107-13
references: 9713906
references: Eur J Clin Pharmacol. 2000 Dec;56(9-10):679-83
references: 11214775
references: Br J Psychiatry. 1991 Jun;158:850-3
references: 1678666
references: Med Clin North Am. 1993 Jan;77(1):185-202
references: 8093494